Trial Outcomes & Findings for Long-Term Assessment of Remyelinating Therapy (NCT NCT02657915)
NCT ID: NCT02657915
Last Updated: 2019-09-23
Results Overview
A full field visual evoked potential (FF-VEP) is an evoked potential caused by a visual stimulus, such as an alternating checkerboard pattern on a computer screen. Responses are recorded from electrodes that are placed on the back of the head and are observed as a reading on an electroencephalogram (EEG). These responses usually originate from the occipital cortex, the area of the brain involved in receiving and interpreting visual signals.
COMPLETED
PHASE2
52 participants
Baseline (RENEW Study [NCT01721161]), Day 1 (NCT02657915)
2019-09-23
Participant Flow
The number of participants eligible for this study was determined by the number of participants who participated in RENEW Study (NCT01721161). A total of 82 participants were enrolled in RENEW Study (NCT01721161) and received at least 1 dose of study treatment. A total of 52 participants participated in this study.
Participant milestones
| Measure |
Placebo
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Overall Study
STARTED
|
24
|
28
|
|
Overall Study
Intent-to Treat (ITT) Population
|
24
|
28
|
|
Overall Study
Per-protocol Population
|
23
|
24
|
|
Overall Study
COMPLETED
|
24
|
28
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Long-Term Assessment of Remyelinating Therapy
Baseline characteristics by cohort
| Measure |
Placebo
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=28 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
Total
n=52 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
35.6 years
STANDARD_DEVIATION 7.96 • n=99 Participants
|
34.6 years
STANDARD_DEVIATION 6.57 • n=107 Participants
|
35.1 years
STANDARD_DEVIATION 7.19 • n=206 Participants
|
|
Sex: Female, Male
Female
|
19 Participants
n=99 Participants
|
19 Participants
n=107 Participants
|
38 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
White
|
4 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Not reported
|
20 Participants
n=99 Participants
|
24 Participants
n=107 Participants
|
44 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline (RENEW Study [NCT01721161]), Day 1 (NCT02657915)Population: Per protocol (PP) population: defined as participants from ITT population who completed the study, did not miss more than 1 dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161). The statistical analysis plan specified that efficacy analyses performed in PP were considered primary analyses.
A full field visual evoked potential (FF-VEP) is an evoked potential caused by a visual stimulus, such as an alternating checkerboard pattern on a computer screen. Responses are recorded from electrodes that are placed on the back of the head and are observed as a reading on an electroencephalogram (EEG). These responses usually originate from the occipital cortex, the area of the brain involved in receiving and interpreting visual signals.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
FF-VEP Latency of the Affected Eye as Compared to the Baseline of the Fellow Eye at 2 Years (+ up to 12 Months) After the Last Study Visit Assessment (Week 32) in RENEW Study (NCT01721161)
Baseline
|
100.68 milliseconds (msec)
Standard Deviation 4.854
|
102.29 milliseconds (msec)
Standard Deviation 5.507
|
|
FF-VEP Latency of the Affected Eye as Compared to the Baseline of the Fellow Eye at 2 Years (+ up to 12 Months) After the Last Study Visit Assessment (Week 32) in RENEW Study (NCT01721161)
Day 1
|
119.52 milliseconds (msec)
Standard Deviation 13.395
|
114.20 milliseconds (msec)
Standard Deviation 14.235
|
SECONDARY outcome
Timeframe: RENEW Study (NCT01721161) to Day 1 (NCT02657915)Population: The PP population was defined as participants from the ITT population who completed the study, did not miss more than one dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161).
The diagnosis of clinically definite multiple sclerosis (CDMS) was made on the basis of clinical criteria and requires that a patient experience at least 2 neurologic events consistent with demyelination, separated both in time and in location in the central nervous system.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Number of Participants That Developed Clinically Definite Multiple Sclerosis (CDMS) After Enrollment in RENEW Study (NCT01721161)
|
12 participants
|
12 participants
|
SECONDARY outcome
Timeframe: RENEW Study (NCT01721161) to Day 1 (NCT02657915)Population: The PP population was defined as participants from the ITT population who completed the study, did not miss more than one dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161).
The diagnosis of CDMS was made on the basis of clinical criteria and requires that a patient experience at least 2 neurologic events consistent with demyelination, separated both in time and in location in the central nervous system. Time to diagnosis of CDMS in Study NCT02657915 was the time from the diagnosis of acute optic neuritis (AON) to the date of confirmed MS. Measured in Days using the Median (50th percentile) for each arm.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Time to Diagnosis of CDMS
|
386.0 days
Interval 212.0 to 1065.0
|
909.5 days
Interval 281.0 to
Data was not reported for this value as it was not observed during this study.
|
SECONDARY outcome
Timeframe: Day 1 (NCT02657915)Population: The PP population was defined as participants from the ITT population who completed the study, did not miss more than one dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161).
The EDSS score is based on neurological testing and an examination of functional systems (FS), which are areas of the central nervous system which control bodily functions. These functional systems are: pyramidal (ability to walk), Cerebellar (coordination), brain stem (speech and swallowing), sensory (touch and pain), bowel and bladder functions, visual, mental and Other (includes any other neurological findings due to MS). An overall score ranging from 0 (normal) to 10 (disability) was calculated. Higher scores indicate greater disability.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Severity of Central Nervous System (CNS) Demyelinating Disease as Assessed Using the Expanded Disability Status Scale (EDSS)
|
1.22 score on a scale
Standard Deviation 0.837
|
1.26 score on a scale
Standard Deviation 1.136
|
SECONDARY outcome
Timeframe: Day 1 (NCT02657915)Population: The PP population was defined as participants from the ITT population who completed the study, did not miss more than one dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161).
SDMT is a screening test for cognitive impairment. Participants were given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). Originate from the occipital cortex, the area of the brain involved in receiving and interpreting visual signals.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Severity of CNS Demyelinating Disease as Assessed Using the Symbol- Digit Modalities Test (SDMT)
|
56.7 score on a scale
Standard Deviation 9.91
|
58.7 score on a scale
Standard Deviation 9.01
|
SECONDARY outcome
Timeframe: Day 1 (NCT02657915)Population: The PP population was defined as participants from the ITT population who completed the study, did not miss more than one dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161).
MSFC has 3 component- timed 25-foot walk (T25FW), 9-hole peg test (9HPT) \[dominant and nondominant hands\] and (3-second) paced auditory serial addition Test (PASAT). The MSFC Z-score is calculated by creating Z-scores for each component of the MSFC and averaging them to create an overall composite score. MSFC Z-score = (Z25-foot-walk + Z9HPT + ZPASAT-3)/3, where Zj refers to Z-scores of component j. A Z-score represented the number of standard deviations participant's test result was higher (Z \>0) or lower (Z \<0) than the average test result (Z = 0) from the reference population. Higher scores indicate better outcomes.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Severity of CNS Demyelinating Disease as Assessed Using the Multiple Sclerosis Functional Composite (MSFC) Assessment
|
-0.82 Z-score
Standard Deviation 2.883
|
-0.06 Z-score
Standard Deviation 0.804
|
SECONDARY outcome
Timeframe: Baseline (RENEW Study [NCT01721161]), Day 1 (NCT02657915)Population: The PP population was defined as participants from the ITT population who completed the study, did not miss more than one dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161).
Change in disease activity from baseline with brain magnetic resonance imaging (MRI) was calculated and reported. MRI analysis included number of consensus GD-enhanced lesions as a measure of disease activity.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Change in Number of Gadolinium (Gd)-Enhanced Lesions From Baseline in RENEW Study (NCT01721161) to Day 1 (NCT02657915)
Baseline
|
0.2 lesions
Standard Deviation 0.69
|
0.1 lesions
Standard Deviation 0.41
|
|
Change in Number of Gadolinium (Gd)-Enhanced Lesions From Baseline in RENEW Study (NCT01721161) to Day 1 (NCT02657915)
Change at Day 1
|
0.2 lesions
Standard Deviation 1.54
|
-0.1 lesions
Standard Deviation 0.46
|
SECONDARY outcome
Timeframe: Baseline (RENEW Study [NCT01721161]), Day 1 (NCT02657915)Population: The PP population was defined as participants from the ITT population who completed the study, did not miss more than one dose of BIIB033 (Opicinumab) or placebo, and did not receive MS modifying therapies in RENEW Study (NCT01721161).
Change in disease activity from baseline with brain magnetic MRI was calculated and reported. MRI analysis included volume of T2 lesions as disease activity.
Outcome measures
| Measure |
Placebo
n=23 Participants
This was a follow-up study with no investigational product administered. Participants in the placebo arm had received at least 1 dose of placebo in RENEW Study (NCT01721161).
|
BIIB033 (Opicinumab) 100 mg/kg
n=24 Participants
This was a follow-up study with no investigational product administered. Participants in the BIIB033 (Opicinumab) arm had received at least 1 dose of 100 milligram per kilogram (mg/kg) BIIB033 in RENEW Study (NCT01721161).
|
|---|---|---|
|
Change in Volume of T2 Lesions From Baseline in RENEW Study (NCT01721161) to Day 1 (NCT02657915)
Baseline
|
0.9710 millilitres (mL)
Standard Deviation 0.93551
|
0.7341 millilitres (mL)
Standard Deviation 1.29222
|
|
Change in Volume of T2 Lesions From Baseline in RENEW Study (NCT01721161) to Day 1 (NCT02657915)
Change at Day 1
|
0.5090 millilitres (mL)
Standard Deviation 1.38861
|
0.6244 millilitres (mL)
Standard Deviation 0.74850
|
Adverse Events
Placebo
BIIB033 (Opicinumab) 100 mg/kg
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.
- Publication restrictions are in place
Restriction type: OTHER